Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. My colleague Ed Silverman, who I view as the foremost expert on drug patents (and coffee flavors), has been taking a closer look at patent claims to bring us an exclusive analysis. We get into all of that today.
The need-to-know this morning
- Organon said it will acquire Dermavant, a subsidiary of Roivant Sciences, for $175 million plus an additional $75 million contingent on expanded approval of VTama, Dermavant’s topical medicine for psoriasis. Roivant will also be eligible for another $950 million tied to the achievement of certain VTama commmercial milestones.
- Applied Therapeutics said the FDA has decided against convening an outside advisory committee to review the company’s drug govorestat for the treament of galactosemia. The FDA review is ongoing, with a decision expected on Nov. 28.
How drugmakers quietly expand their patent claims
Drugmakers are understandably eager to expand their patents. A new STAT analysis shows one way in which they do that through the Orange Book, a key FDA registry.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
